RSV Seasonal Vaccine Introduction and Growth Strategy
Purpose: to get ahead of disease together
For health impact, shareholder returns and thriving people
Six priority areas to build trust
Access
Environment
Global health and
health security
Diversity, equity
and inclusion
Key highlights
Access
In July, Gavi announced the first nine new countries to be allocated
doses of the RTS,S/AS01E vaccine against malaria from early 2024
Global Health and Health Security
Gates Foundation and Wellcome announced funding for the phase III
trial of M72/AS01E candidate vaccine against tuberculosis, developed
up to phase II by GSK
||
Environment
Selected by The Science Based Target Network to set science-based
targets for nature, building on our existing nature targets
Product governance
Ethical standards
GSK
29
20View entire presentation